CeriBell, Inc. CEO Jane Chao will present at the J.P. Morgan Healthcare Conference on January 12, 2026.
Quiver AI Summary
CeriBell, Inc., a medical technology company based in Sunnyvale, California, will have its CEO and co-founder, Jane Chao, Ph.D., present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 9:00 am PST. The company focuses on improving the diagnosis and management of serious neurological conditions with its innovative Ceribell System, a point-of-care electroencephalography platform. This system combines portable hardware with advanced AI algorithms to facilitate rapid diagnosis and continuous monitoring of neurological patients, and it is FDA-cleared for use in detecting seizures and delirium in critical care settings. Live and archived webcasts of the presentation will be accessible on their website.
Potential Positives
- Ceribell's CEO, Jane Chao, will present at the prestigious 44th Annual J.P. Morgan Healthcare Conference, highlighting the company's visibility in the medical technology sector.
- The Ceribell System is FDA-cleared for detecting seizure and delirium in critical care settings, demonstrating regulatory approval and the product's potential impact on patient care.
- The innovative design of the Ceribell System incorporates AI technology, showcasing the company's commitment to leveraging advanced technology in healthcare solutions.
- The press release provides direct links to further information and future webcasts, enhancing transparency and engagement with investors and stakeholders.
Potential Negatives
- The press release does not provide any financial performance metrics or forecasts, which could raise concerns about the company's current financial health and future prospects.
- The lack of details regarding the specifics of the upcoming presentation at the J.P. Morgan Healthcare Conference may indicate a lack of significant new developments to share with investors and stakeholders.
- There is no information about recent product performance or market reception, which may suggest challenges in gaining traction for the Ceribell System in a competitive market.
FAQ
What is the date and time of Ceribell's presentation at the J.P. Morgan Healthcare Conference?
Ceribell's presentation will take place on January 12, 2026, at 9:00 am PST / 12:00 pm EST.
Where can I watch the live webcast of the Ceribell presentation?
The live webcast will be available in the "Investor Relations" section of the Ceribell website.
Who is the CEO of Ceribell presenting at the conference?
Jane Chao, Ph.D., is the CEO and Co-founder of Ceribell presenting at the conference.
What technology does Ceribell specialize in?
Ceribell specializes in medical technology for diagnosing and managing serious neurological conditions with their EEG platform.
Is the Ceribell System FDA-cleared for any uses?
Yes, the Ceribell System is FDA-cleared for detecting seizures and delirium in acute care settings.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CBLL Insider Trading Activity
$CBLL insiders have traded $CBLL stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $CBLL stock by insiders over the last 6 months:
- XINGJUAN CHAO (President and CEO) has made 0 purchases and 4 sales selling 125,000 shares for an estimated $2,084,250.
- JOSEF PARVIZI has made 0 purchases and 2 sales selling 50,000 shares for an estimated $1,043,750.
- SCOTT BLUMBERG (Chief Financial Officer) has made 0 purchases and 3 sales selling 36,000 shares for an estimated $756,000.
- WILLIAM W BURKE has made 0 purchases and 2 sales selling 32,728 shares for an estimated $720,670.
- RAYMOND WOO (Chief Technology Officer) has made 0 purchases and 4 sales selling 44,448 shares for an estimated $546,821.
- REBECCA B ROBERTSON has made 0 purchases and 3 sales selling 6,654 shares for an estimated $123,180.
- DAVID FOEHR (Senior VP, Finance and PAO) has made 0 purchases and 4 sales selling 6,131 shares for an estimated $98,750.
- JOSEPH MICHAEL TAYLOR sold 7,032 shares for an estimated $82,696
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CBLL Hedge Fund Activity
We have seen 51 institutional investors add shares of $CBLL stock to their portfolio, and 37 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NOVO HOLDINGS A/S removed 900,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $10,341,000
- CENTERBOOK PARTNERS LP added 389,584 shares (+448.0%) to their portfolio in Q3 2025, for an estimated $4,476,320
- FMR LLC removed 357,399 shares (-7.4%) from their portfolio in Q3 2025, for an estimated $4,106,514
- SOLEUS CAPITAL MANAGEMENT, L.P. added 310,000 shares (+620.0%) to their portfolio in Q3 2025, for an estimated $3,561,900
- LORD, ABBETT & CO. LLC removed 295,769 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $3,398,385
- NEXT CENTURY GROWTH INVESTORS LLC removed 199,082 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,287,452
- MILLENNIUM MANAGEMENT LLC added 196,299 shares (+41.8%) to their portfolio in Q3 2025, for an estimated $2,255,475
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CBLL Analyst Ratings
Wall Street analysts have issued reports on $CBLL in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 12/15/2025
- JP Morgan issued a "Overweight" rating on 11/05/2025
- TD Cowen issued a "Buy" rating on 11/05/2025
- Raymond James issued a "Strong Buy" rating on 10/21/2025
To track analyst ratings and price targets for $CBLL, check out Quiver Quantitative's $CBLL forecast page.
$CBLL Price Targets
Multiple analysts have issued price targets for $CBLL recently. We have seen 5 analysts offer price targets for $CBLL in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- William Plovanic from Canaccord Genuity set a target price of $30.0 on 12/17/2025
- Marie Thibault from BTIG set a target price of $30.0 on 12/15/2025
- Joshua Jennings from TD Cowen set a target price of $20.0 on 11/05/2025
- Robbie Marcus from JP Morgan set a target price of $17.0 on 11/05/2025
- Jayson Bedford from Raymond James set a target price of $19.0 on 10/21/2025
Full Release
SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 44 th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 12, 2026, at 9:00 am Pacific Standard Time / 12:00 pm Eastern Standard Time.
Event: 44
th
Annual J.P. Morgan Healthcare Conference
Date: Monday, January 12, 2026
Time: 9:00 am PST / 12:00 pm EST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/ .
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on
LinkedIn
.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
[email protected]
Media Contact
Brian Price
[email protected]
